Brief Description
This initiative supports independent medical education programs designed to increase healthcare professional (HCP) competence, clinical confidence, and multidisciplinary coordination in the safe and effective use of BCMA-directed bispecific antibodies (BsAbs) in the 2nd line and later (2L+) relapsed/refactory multiple myeloma (RRMM) setting.